Citations

Clear

9383 citation(s) found for "Thomas, PS".

The Society of Thoracic Radiology Mentorship Program
Koo, Chi Wan , Sundaram, Baskaran , McGuinness, Georgeann , Haramati, Linda B.

Mayo Clinic

Journal of Thoracic Imaging | May 12, 2025 | Volume: 40 | Issue: 5 | Pages: No page available

10.1097/rti.0000000000000834 | PMID 40351274 Get It

The Society of Thoracic Radiology (STR) membership enthusiastically embraced the launch of its mentorship program, with peaks in participation and engagement after annual meetings and during the COVID pandemic. The program provides a valuable resource for early to mid-career thoracic radiologists, especially those lacking local resources. This report describes the program’s inception and design, and summarizes the program’s successes and challenges at 5 years, based on a 2023 mentorship survey. STR mentees, spanning early to mid-career stages, most frequently sought mentorship in career development, graduate medical education, research portfolio development, publishing, cardiac imaging, grant funding, and artificial intelligence. Mentors offered expertise in these areas, plus lung cancer screening, career development, and workplace navigation. The committee prioritized creating dyads based on mutual interest and expertise, achieving mutual top-choice match rates of 70% to 97%. Enduring dyads flourished as the program matured. At 5 years, a survey of participants was fielded. Mentees reported moderate to high program impact on scholarly activities, leadership, networking, clinical service, education, and career satisfaction. Mentors described satisfaction in their roles, highlighting networking, career satisfaction, and the opportunity to influence upcoming generations of cardiothoracic radiologists, thereby impacting the field’s future. Most participants expressed high career satisfaction. Descriptive comments further enriched findings. Survey results confirmed that strengthening dyad formation and enhancing mentoring outcomes remain pivotal. Remote mentorship, while valuable, presents challenges—personal connections and contextual familiarity, considered essential to successful mentorship relationships, are typically absent in these settings. Activities to potentially enhance the STR mentorship program are offered.
Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective
Gulati, Ankit, Kane, Sunanda V. , Creveling, Thomas, Bires, Nicholas, Fisher, Deborah A. , Chanan, Neha, Koushik, Amit Kumar, Upadhyay, Navneet , Gulati, Ankit, Mittal, Neha

Mayo Clinic

Journal of Medical Economics | May 12, 2025 | Volume: 28 | Issue: 1 | Pages: 709-718

10.1080/13696998.2025.2503661 | PMID 40351121 Get It

Tracheal Chondrosarcoma Presenting as Variable Extrathoracic Airway Obstruction Surgically Resected on Veno-venous Extracorporeal Membrane Oxygenation
Mangin, W.W., Thomas, C, Mangin, W W, Thomas, C.F.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4861-A4861

10.1164/ajrccm.2025.211.abstracts.a4861 Get It

Abstract Tracheal tumors are uncommon, comprising only 0.2% of respiratory tract malignancies, with the majority of these being squamous cell carcinoma and adenoid cystic carcinoma. Tracheal chondrosarcomas are a rare cause, with only thirty-four cases described in literature between 1959 and 2020. Although often asymptomatic, nonspecific symptoms including dyspnea, nonproductive cough, and wheezing contribute towards misdiagnosis with diseases such as asthma or chronic obstructive pulmonary disease (COPD). Delay in diagnosis can potentially lead to complete tracheal obstruction and airway compromise. Treatment of choice is surgical resection, with overall 10-year survival to be around 95%. Although recurrence rates are minimal when treated with open surgical resection with negative margins, post-surgical surveillance is recommended. Use of extracorporeal membrane oxygenation (ECMO) during surgery offers an alternative to endotracheal intubation, potentially making complete tumor resection easier. A 56-year-old male never smoker with past medical history of hereditary hemochromatosis, requiring phlebotomy, severe obstructive sleep apnea status post right upper airway nerve stimulator placement, and a history of left vocal cord granuloma that presented to an outpatient pulmonology clinic for chronic cough and exertional dyspnea. Initially, the patient was started on a proton pump inhibitor and nasal corticosteroid, without improvement in symptoms. He subsequently underwent pulmonary function testing, which showed flow volume loop suspicious for variable extrathoracic airway obstruction. Chest computed tomography (CT) scan was significant for a 2.2 cm soft tissue lesion in the left upper mediastinum with protrusion through the tracheal wall. PET scan did not show significant FDG avidity. A 1.5 centimeters lesion situated about 5 centimeters above the carina was found on rigid bronchoscopy and biopsies were negative for malignancy. Patient subsequently underwent video-assisted thoracoscopic surgery (VATS) robotic-assisted tracheal resection on Veno-venous ECMO. Final pathology was consistent with G1 chondrosarcoma, with negative margins. On follow up, patient's respiratory symptoms have resolved and periodic surveillance with repeat chest CTs is planned. This unique case offers an important reminder of a potential cause of upper airway obstruction, not only highlighting the potential of pulmonary function testing to aid in early detection, but also the successful use of ECMO in surgical resection.
Finding the Best Fit: A Head-To-Head Comparison of Triple Therapy Regimens in COPD
Versha, Fnu, Lohana, Abhichand, Patel, Viral , Iribarren, JL, LOHANA, ABHI , Chander, Subhash , Iribarren, J.B.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4032-A4032

10.1164/ajrccm.2025.211.abstracts.a4032 Get It

Abstract Introduction: Chronic obstructive pulmonary disease (COPD) represents a significant global health challenge, particularly in its moderate to severe cases, where effective management is crucial to improving patient outcomes. The integration of inhaled corticosteroids with long-acting β2-adrenoceptor agonists and long-acting muscarinic antagonists in fixed-dose combinations has emerged as a cornerstone of therapy. This study evaluates the efficacy of two triple therapy regimens — Glycopyrrolate, Budesonide, and Formoterol Fumarate (GLY/BUD/FOR) and Fluticasone Furoate, Vilanterol, and Umeclidinium (FF/VI/UMEC) —in adults aged 45 and older with diagnosed COPD with FEV1/FVC < 70% to assess the impact of these regimens on the preventing COPD exacerbations and acute hypoxemic respiratory failure. Methods: A retrospective cohort analysis was conducted using the TriNetX database. Patients with moderate to severe COPD and FEV1/FVC < 70% were identified based on ICD codes, and two cohorts were formed based on the prescribed inhaler therapy: GLY/BUD/FOR and FF/VI/UMEC. Patients with comorbid asthma, heart failure, or pneumonia were excluded. A 1:1 propensity-score matching (PSM) analysis was performed to balance covariates such as age, gender, smoking status, and baseline lung function to minimize confounding and bias. Post-matching, both had 16,052 patients. Ultimately, 23,331 patients (FF/VI/UMEC: 11,234, GLY/BUD/FOR: 12,097) with a mean age of 67.4 ± 10.1 years and 55.3% males were included. Results: Among groups, 10.4% of patients on FF/VI/UMEC experienced COPD exacerbations compared to 6.7% on GLY/BUD/FOR (Risk Ratio: 1.55, 95% CI: 1.42-1.69, p < 0.001). Kaplan-Meier analysis showed a lower survival probability in the FF/VI/UMEC group (77.7% vs. 83.9%, p < 0.001). For acute respiratory failure, 3.5% of patients on FF/VI/UMEC experienced this outcome compared to 2.8% on GLY/BUD/FOR (Risk Ratio: 1.28, 95% CI: 1.12-1.45, p = 0.003). Conclusion: Our study suggests that FF/VI/UMEC demonstrated an increased risk of COPD exacerbations and acute hypoxic respiratory failure compared to the group receiving GLY/BUD/FOR. This indicates that GLY/BUD/FOR may provide enhanced protective benefits in patients with moderate to severe COPD, improving disease management and minimizing healthcare resource utilization. Further studies are warranted to explore the long-term benefits and potential mechanisms underlying the observed differences.
Clinical Outcomes of Patients With Idiopathic or Lymphocytic Hypereosinophilic Syndrome in the United States: A Real-world Retrospective Observational Cohort Study
Pongdee, Thanai , Dolin, P., Ding, Bo , Rowell, Jennifer , Edmonds, Carl, Eudicone, James M. , Moore, Andrew M. , Peer, Thomas , Chen, S.Y., Dolin, P., Jain, Priya Narayanan , Edmonds, C., Moore, A.M., Peer, T., Chan, K. Arnold

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3201-A3201

10.1164/ajrccm.2025.211.abstracts.a3201 Get It

Abstract RATIONALE: Hypereosinophilic syndrome (HES) is a group of rare diseases characterized by persistent hypereosinophilia causing organ damage/dysfunction. Idiopathic and lymphocytic HES (I-HES/L-HES) subgroups exclude clonal and reactive HES. We evaluated real-world clinical outcomes of patients with I-HES/L-HES. METHODS: This retrospective observational cohort study of patients with I-HES/L-HES collected data from the TriNetX Linked Network of de-identified Electronic Health Records plus Claims in the US. Patients had a HES diagnosis (ICD-10-CM: D72.11) between 10/01/2020–09/12/2023, with ≥12 months continuous enrollment before their first HES diagnosis record (index date [ID]). Patients with myeloproliferative/reactive HES, or a diagnosis of eosinophilic granulomatosis with polyangiitis after HES diagnosis, were excluded. Baseline was defined as 12 months prior to ID. Year 1 was defined as 12 months after ID. Patients were followed up until either 09/12/2023, disenrollment from insurance, death, or 24 months after ID, whichever came first. Clinical response was defined as ≥3 months without HES symptoms and a blood eosinophil (bEOS) count ≤750 cells/µL. Complete hematological remission was defined as a bEOS count ≤500 cells/µL. Partial remission was defined as a bEOS count <50% of baseline value, but >500 cells/µL. Kaplan-Meier curves estimated time to first HES flare and hematological remission. Analyses were descriptive. RESULTS: At ID, patients with I-HES/L-HES (N=110) had a mean (standard deviation [SD]) age of 43.8 (21.3) years; 66 (60.0%) were male, 58 (52.7%) were White and 30 (27.3%) were Black or African American. Mean (SD) follow-up was 15.1 (7.7) months. Median (95% confidence interval [CI]) time from ID to first flare (n=47) was 18.0 (11.0, not estimated) months (Table 1). Median (95% CI) time to first complete or partial hematological remission (n=52) was 15.3 (10.8, 21.6) months. The proportion of patients with a definite or probable HES flare was lower at Year 1 (10/69 [14.5%]) versus baseline (40/110 [36.4%]). Few patients achieved clinical response at baseline (10/110 [9.1%]) and Year 1 (5/69 [7.2%]). Among patients with bEOS data, mean (SD) bEOS count was 2235.3 (4351.7) cells/µL at baseline (n=51) and 833.6 (1396.0) cells/µL at Year 1 (n=11). The proportion of patients with a bEOS count <500 cells/µL was 20/51 (39.2%) at baseline and 7/11 (63.6%) at Year 1. CONCLUSION: Despite a reduced proportion of patients experiencing flares within a year after diagnosis, many did not experience hematological remission or clinical response by Year 1; suggesting high disease burden with existing treatment and the need for novel therapies to better manage I-HES/L-HES.
The Impact of Reconnecting With Survivors After Critical Illness on Clinical Practice and Job Satisfaction in Nursing: A Mixed-Methods Survey
Eaton, Tammy L. , Boehm, Leanne M. , Lagina, Madeline , Valley, Thomas S. , Danesh, Valerie , McPeake, Joanne , Potter, Kelly , Lindroth, Heidi , Taylor, Stephanie Parks

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3143-A3143

10.1164/ajrccm.2025.211.abstracts.a3143 Get It

Abstract Rationale: ICU nurses can experience high levels of burnout and job dissatisfaction due to stressors associated with high-stakes patient care, uncertain outcomes, and constant exposure to death. Witnessing patient recovery and/or disability status in the weeks or months after hospital discharge through reconnection with survivors of critical illness and their families may offer emotional and professional benefits to ICU nurses. However, the impact of connecting with patients’ post-ICU outcomes on nursing clinical practice and job satisfaction has not been well explored. This study aimed to investigate pragmatic perspectives from ICU nurses related to their insights on long-term patient outcomes after critical illness with a goal of identifying key mechanisms that may be associated with impacts on clinical practice and job satisfaction. Methods: A web-based investigator-designed survey was distributed to ICU nurses with endorsement from the American Association of Critical-Care Nurses for completion via their website and annual conference. Survey items included quantitative and open-ended prompts to examine the impact of reconnecting with ICU survivors on clinical practice and job satisfaction. Thematic analysis was performed on free-text responses. Results: Fifty-four ICU nurses (76% female) participated in the survey (June 2023-May 2024), with a median age of 41 years and a median of 7 years of critical care experience. Among them, 89% reported that reconnecting with survivors positively impacted their job satisfaction, and 78% felt that reconnecting influenced their clinical practice. Thematic analysis revealed three themes: Empathy and Human Connection – Nurses felt validated and fulfilled knowing their care positively impacted patients’ lives, reinforcing the meaning of their work. These interactions fostered greater empathy, reminding nurses of the real-life impact of their care.Validation of Effort and Accomplishment – Nurses reported a stronger sense of accomplishment seeing the positive outcomes of their work. Reconnecting with survivors reaffirmed the importance of their roles, strengthening nurses’ sense of purpose and commitment.Positive Emotional Impact and Job Satisfaction – Interactions with survivors provided emotional uplift, enhancing job satisfaction and reminding nurses of the rewarding aspects of their roles. Gratitude and progress from survivors motivated nurses, helping them manage the emotional challenges of ICU work. Conclusion: Reconnecting with ICU survivors and their families may have positive impacts on job satisfaction and clinical practice by providing emotional rewards, reinforcing nurses’ professional purpose, and validating their contributions to patient recovery. Embedding structured, low-cost re-engagement activities with critical illness survivors could offer valuable benefits to the ICU nurse workforce.
Assessing the Accuracy of the Veteran Specific Activity Questionnaire in Predicting Maximum Oxygen Consumption in Adults Undergoing Cardiopulmonary Exercise Testing at a Tertiary Care Center
Allison, Thomas G. , Puentes, G.A. Cortes, Phillips, A., Lim, Kaiser G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1983-A1983

10.1164/ajrccm.2025.211.abstracts.a1983 Get It

Abstract Rationale: Cardiopulmonary exercise testing is a unique tool for simultaneously assessing cardiopulmonary and metabolic responses at peak exercise, making it invaluable for diagnosing unexplained dyspnea and fatigue, common issues in cardiovascular and pulmonary clinics. However, its use is often limited by complex guidelines, restricted lab access, technical demands, and high costs. The Veterans Specific Activity Questionnaire (VSAQ), developed by Meyers et al., offers a practical way to estimate metabolic equivalents and maximum oxygen consumption to assess exercise capacity. While primarily validated in a male population, the VSAQ lacks sufficient research in diverse ethnic and gender groups. Broader validation could enhance personalized cardiopulmonary testing, support equitable healthcare resource allocation, and help lower costs. Methods: In this prospective observational study, participants were included if they were 18 years or older and capable of completing a cardiopulmonary exercise test. Participants were excluded if they had known abnormal breathing patterns at baseline and if they had any contraindication for cardiopulmonary exercise and pulmonary function testing. A total of 17 patients without known cardiopulmonary disease provided informed consent and completed the brief self-administered VSAQ following the cardiopulmonary exercise test. The VSAQ was used to estimate maximal exercise capacity in metabolic equivalents, which was then compared to the actual maximal exercise capacity achieved on a bike ergometer, as recorded in the electronic medical records. Results: A linear regression analysis indicated a marginal association between VSAQ results (METS) and CPET METS, accounting for 22.2% of the variance in CPET METS (p=0.056). This finding suggests a potential, though not statistically significant, positive relationship between VSAQ METS scores and CPET MET. A linear regression analysis indicated a marginal association between VSAQ calculated Peak VO₂ and observed CPET Peak VO₂ (o₂/kg/min), explaining 21.6% of the variance in CPET Peak VO₂ (p=0.060). This suggests a potential positive relationship between VSAQ calculated Peak VO₂ and CPET Peak VO₂, though the association did not reach statistical significance. Conclusion: In this preliminary sample of patients without known cardiopulmonary disease, the VSAQ demonstrated accuracy in predicting maximum oxygen consumption at peak exercise. With further validation and larger sample size, the VSAQ could become a valuable adjunctive tool for assessing patients with unexplained dyspnea and fatigue, supporting more efficient diagnostic evaluations. Additionally, the VSAQ may serve as a practical follow-up measure to track clinical improvement after therapeutic interventions in this specific population.
Association of Obesity With Mortality, ARDS, and Thromboembolism in ICU Patients on Prolonged Ventilation
LOHANA, ABHI , Versha, Fnu, Kumar, B., Khawar, Muhammad Umair , Patel, Viral , Akbar, Usman Ali , Chander, Subhash

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1504-A1504

10.1164/ajrccm.2025.211.abstracts.a1504 Get It

Abstract Introduction: Obesity's increasing prevalence significantly impacts Intensive Care Unit (ICU) patient outcomes, especially for those requiring prolonged mechanical ventilation. This study investigates the effect of Body Mass Index (BMI) on mortality and complications—such as acute respiratory distress syndrome (ARDS), pulmonary embolism (PE), and deep vein thrombosis (DVT)—in ICU patients intubated for over 96 hours. Methods: We conducted a retrospective cohort study using the TriNetX database to identify patient populations with relevant ICD codes. Patients who had received anticoagulation and had been on mechanical ventilation for more than 96 hours were included. Cohort 1 consisted of patients with a BMI of 30-44.9 kg/m² (n = 70,379), and Cohort 2 included patients with a BMI of 18.5-29.9 kg/m² (n = 111,054). Both cohorts were matched using propensity score matching (PSM), resulting in balanced groups of 47,233 patients. The mean age was 64.3 ± 15.1 years in Cohort 1 and 64.5 ± 16.5 years in Cohort 2, with a male predominance of 57.9% in both cohorts after matching. Outcomes (mortality, PE, DVT, and ARDS) were identified using ICD-10 codes and analyzed on Days 14, 30, and 90. Results: Higher BMI was associated with increased all-cause mortality across all measured time points. By Day 14, mortality was 23.0% in Cohort 1 versus 19.2% in Cohort 2 (RiskRatio [RR]: 1.196; 95% CI: 1.166-1.226). By Day 90, mortality reached 37.6% in Cohort 1 compared to 32.6% in Cohort 2 (RR: 1.151; 95% CI: 1.132-1.171). Additionally, the risk of developing ARDS was higher in Cohort 1, with statistically significant risk ratios observed on Day 14 (RR: 1.117; 95% CI: 1.020-1.222) and Day 30 (RR: 1.094; 95%CI: 1.010-1.186). PE risk in Cohort 1 significantly increased by Day 30 (RR: 1.119; 95% CI: 1.008-1.243), while DVT risk was also elevated in Cohort 1 at both Day 14 (RR:1.140; 95% CI: 1.037-1.253) and Day 30 (RR: 1.129; 95% CI: 1.040-1.224). Conclusion: Higher BMI in mechanically ventilated ICU patients intubated for more than 96 hours is associated with increased mortality and a higher incidence of complications, including ARDS, PE, and DVT. This study contributes to our understanding of BMI's impact on ICU outcomes, highlighting critical areas for improved clinical management in this population and the need for targeted interventions in obese ICU patients, such as optimized respiratory support and monitoring for thromboemboliccomplications.
Study of Soy Isoflavones (SOYA) Responder Analysis Among Patients Who Have 4G4G/4G5G Serine Protease Inhibitor Family E Member 1 (SERPINE1) Genotypes
Fowler, John R. , Cardet, J.C., Mhaskar, Rahul , Baptist, Alan P. , Dixon, Anne E. , Hanania, N.A., Israel, Elliot , Garrow, O.J., Moy, James N., Riley, Isaretta , Wang, J.G., Fowler, J., Nguyen, D.T., Casale, Thomas B. , Chiarella, Sergio E. , Garrow, Olivia Johnson, Nyenhuis, Sharmilee Maria , Smith, Lewis J. , Wu, Timothy , Cho, Seong , Kumar, Rajesh

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1344-A1344

10.1164/ajrccm.2025.211.abstracts.a1344 Get It

Abstract RATIONALE: 4G4G/4G5G SERPINE1 genotypes produce high concentrations of plasminogen activator inhibitor-1 and are associated with worse asthma outcomes. A secondary analysis of the American Lung Association (ALA) SOYA trial showed that soy isoflavones significantly reduced asthma exacerbations versus placebo among patients with 4G4G/4G5G SERPINE1 genotypes. We hypothesized that baseline characteristics predict optimal responders to soy isoflavones among this subgroup. METHODS: ALA-SOYA was a randomized controlled trial that tested the efficacy of soy isoflavones vs. placebo for reducing asthma exacerbations among adolescents and adults with symptomatic asthma. In this responder analysis among participants with 4G4G/4G5G SERPINE1 genotypes, baseline demographic and clinical characteristics were tested for effect modification of the treatment assignment (soy/placebo) on the primary outcome of annualized number of asthma exacerbations using interaction terms in negative binomial regression models, with a significance threshold of p-interaction=0.15. RESULTS: Data were available for n=168 participants. Soy reduced the annualized number of asthma exacerbations relative to placebo among patients with 4G4G/4G5G SERPINE1 genotypes (incident rate ratio (IRR)=0.37, 95% confidence interval (CI): 0.15-0.90, p=0.028). Self-reported adherence to baseline controller therapy was the only significant effect modifier of this association (interaction p=0.115), with those using inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) controller therapy at least twice weekly experiencing reductions in asthma exacerbations with soy versus placebo (IRR = 0.25, 95% CI: 0.09-0.69; p= 0.007) but not among those using ICS/LABA controller therapy less frequently (IRR = 1.33, 95% CI: 0.22-8.02; p= 0.757). CONCLUSION: Soy isoflavones reduce asthma exacerbations among patients with the 4G4G/4G5G SERPINE1 genotypes and are most effective in those with greater adherence to asthma controller therapy regimens.
Outcomes With ABO Identical Versus ABO Compatible Blood Groups in Patients Undergoing Lung Transplantation
Balasubramanian, P., Bongu, R., Francisco, Angel de, Baz, Maher A. , Narula, Tathagat , Haney, John C. , Makey, Ian A. , Thomas, M., Alomari, M., Francisco, A., Shah, Sadia , Bag, Remzi

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1112-A1112

10.1164/ajrccm.2025.211.abstracts.a1112 Get It

Abstract Introduction: The data on outcomes comparing lung transplantation with ABO-identical versus ABO-compatible blood group is limited. Composite Allocation Score(CAS) was introduced on March 9th, 2023, and has considered additional points for the difficult-to-match blood group. We aimed to study the trend and outcomes of patients who underwent lung transplants with ABO identical versus compatible blood groups. Methods: We queried the United Network of Organ Sharing (UNOS) database of those who underwent lung transplantation between 10/1/1987 to 3/31/2024 and compared the outcomes between those who had ABO-identical vs ABO-compatible blood groups. Combined organ transplants and recipients age <18 were excluded. Results: A total of 50,406 patients were included in our study, out of which 4,111 (8.15%) were ABO-compatible and 47,347 (91.85%) were ABO-identical. Among the recipient demographics, the ABO-compatible group compared to the ABO-identical group showed a lesser lung allocation score (40 ± 16 vs 42 ± 16), but higher A-blood group (59% vs 38%), obstructive lung disease (38% vs 33%), CAS (49 ± 13 vs 47 ± 10), mechanical ventilator support pre-transplant (6.2% vs 5.2%), need for ex-vivo lung perfusion (9.6% vs 5.8%) and listing for single lung transplant (39% vs 34%), all p<0.05. The donors for the ABO-compatible group had a closer distance to the transplant center (205 ± 285 vs 226 ± 265 nautical miles), lesser white race (61% vs 64%), and gender mismatch (30% vs 32%) but higher male gender (64% vs 61%), O-blood group (81% vs 49%) and ethnicity mismatch (45% vs 41%), all p<0.05. The univariate analysis showed a higher 30-day (7.2% vs 5.8%), 1-year (22% vs 19%), and 5-year (54% vs 50%) mortality among patients with ABO-compatible compared to ABO-identical recipients, all p<0.001. However, the adjusted odds ratio of 30-day (0.76, 95% CI 0.36-1.47, p=0.4), 1-year (1.07, 95% CI 0.69-1.66, p=0.7) and 5-year (0.69, 95% CI 0.46-1.05, p=0.081) mortality were not statistically significant with ABO-identical when compared to ABO-compatible group on adjusting to the covariates in the multivariate analysis. The trend of ABO-compatible lung transplantation has been increasing with the introduction of CAS (figure 1). Conclusion: Patients who underwent lung transplantation with the ABO-compatible blood group donor organs had similar outcomes compared to the ABO-identical blood group. The findings of our study reinforce the importance of increasing the use of ABO-compatible organs to enhance the lung transplantation rate, aligning with the observed trend following the introduction of CAS.